Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis. / Hamann, Carsten R; Thyssen, Jacob P.

I: Journal of the American Academy of Dermatology, Bind 78, Nr. 3, Supplement 1, 2018, s. S37-S42.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Hamann, CR & Thyssen, JP 2018, 'Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis', Journal of the American Academy of Dermatology, bind 78, nr. 3, Supplement 1, s. S37-S42. https://doi.org/10.1016/j.jaad.2017.12.018

APA

Hamann, C. R., & Thyssen, J. P. (2018). Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis. Journal of the American Academy of Dermatology, 78(3, Supplement 1), S37-S42. https://doi.org/10.1016/j.jaad.2017.12.018

Vancouver

Hamann CR, Thyssen JP. Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis. Journal of the American Academy of Dermatology. 2018;78(3, Supplement 1):S37-S42. https://doi.org/10.1016/j.jaad.2017.12.018

Author

Hamann, Carsten R ; Thyssen, Jacob P. / Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis. I: Journal of the American Academy of Dermatology. 2018 ; Bind 78, Nr. 3, Supplement 1. s. S37-S42.

Bibtex

@article{a832709320e744ceaccf2dcea7299d54,

title = "Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis",

abstract = "The interleukin 13 (IL-13) and IL-31 cytokines and inflammatory pathways have been identified as important for the pathophysiology of atopic dermatitis (AD). Monoclonal antibodies against IL-13 have been studied for the treatment of asthma since 2011. More recently, 2 phase 2 trials have been completed with these antibodies in AD treatment. In both trials, significant reductions of Eczema Area and Severity Index scores were seen. IL-31 is thought to play a role transmitting itch sensation to the central nervous system, and blocking IL-31 activity reduces itch in patients with AD. One phase 2 trial has been completed for a humanized antibody against IL-31 receptor alpha, which is 1 subunit of the IL-31 receptor complex. This study showed significant dose-dependent reductions in pruritus, Eczema Area and Severity Index scores, and markers of sleep quality. Initial clinical trials for monoclonal antibodies against IL-13 and IL-31 receptor A all show promise, although long-term safety and efficacy data are lacking. Nevertheless, these medications will likely play a role in the treatment of moderate-to-severe AD.",

author = "Hamann, {Carsten R} and Thyssen, {Jacob P}",

year = "2018",

doi = "10.1016/j.jaad.2017.12.018",

language = "English",

volume = "78",

pages = "S37--S42",

journal = "American Academy of Dermatology. Journal",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "3, Supplement 1",

}

RIS

TY - JOUR

T1 - Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis

AU - Hamann, Carsten R

AU - Thyssen, Jacob P

PY - 2018

Y1 - 2018

N2 - The interleukin 13 (IL-13) and IL-31 cytokines and inflammatory pathways have been identified as important for the pathophysiology of atopic dermatitis (AD). Monoclonal antibodies against IL-13 have been studied for the treatment of asthma since 2011. More recently, 2 phase 2 trials have been completed with these antibodies in AD treatment. In both trials, significant reductions of Eczema Area and Severity Index scores were seen. IL-31 is thought to play a role transmitting itch sensation to the central nervous system, and blocking IL-31 activity reduces itch in patients with AD. One phase 2 trial has been completed for a humanized antibody against IL-31 receptor alpha, which is 1 subunit of the IL-31 receptor complex. This study showed significant dose-dependent reductions in pruritus, Eczema Area and Severity Index scores, and markers of sleep quality. Initial clinical trials for monoclonal antibodies against IL-13 and IL-31 receptor A all show promise, although long-term safety and efficacy data are lacking. Nevertheless, these medications will likely play a role in the treatment of moderate-to-severe AD.

AB - The interleukin 13 (IL-13) and IL-31 cytokines and inflammatory pathways have been identified as important for the pathophysiology of atopic dermatitis (AD). Monoclonal antibodies against IL-13 have been studied for the treatment of asthma since 2011. More recently, 2 phase 2 trials have been completed with these antibodies in AD treatment. In both trials, significant reductions of Eczema Area and Severity Index scores were seen. IL-31 is thought to play a role transmitting itch sensation to the central nervous system, and blocking IL-31 activity reduces itch in patients with AD. One phase 2 trial has been completed for a humanized antibody against IL-31 receptor alpha, which is 1 subunit of the IL-31 receptor complex. This study showed significant dose-dependent reductions in pruritus, Eczema Area and Severity Index scores, and markers of sleep quality. Initial clinical trials for monoclonal antibodies against IL-13 and IL-31 receptor A all show promise, although long-term safety and efficacy data are lacking. Nevertheless, these medications will likely play a role in the treatment of moderate-to-severe AD.

U2 - 10.1016/j.jaad.2017.12.018

DO - 10.1016/j.jaad.2017.12.018

M3 - Journal article

C2 - 29248521

VL - 78

SP - S37-S42

JO - American Academy of Dermatology. Journal

JF - American Academy of Dermatology. Journal

SN - 0190-9622

IS - 3, Supplement 1

ER -

ID: 197370415